Canine freeze-dried plasma could expand emergency transfusion access

Version 2 — Full analysis

A shelf-stable canine plasma product could change one of the biggest constraints in veterinary transfusion medicine: access. Mantel Technologies’ canine freeze-dried plasma, or cFDP, is designed for treatment of hypovolemia and control of hemorrhage in dogs, and unlike fresh frozen plasma, it does not require frozen storage before use. In a December 18, 2025 update, the FDA said it had completed its risk review and did not intend to object to marketing the product at that time, opening the door for broader veterinary use. (fda.gov)

That matters because plasma has long been useful in trauma and coagulopathy, but hard to deploy quickly outside well-equipped hospitals. Traditional fresh frozen plasma must be stored frozen, maintained through a cold chain, and thawed before administration. Freeze-dried plasma changes that workflow by allowing room-temperature storage before reconstitution. In a 2021 review of emerging resuscitation products, researchers described freeze-dried plasma as a Department of Defense priority because it can be reconstituted in under five minutes and used when whole blood is not readily available. The same review noted that canine products from Mantel and another company were being developed with DoD support. (frontiersin.org)

The regulatory details are important. FDA reviewed Mantel’s cFDP as an animal cell, tissue, and cell- and tissue-based product, not as a traditionally approved drug. The agency said the product is not approved, conditionally approved, or index listed, but concluded that Mantel had appropriately identified and mitigated risks and that FDA had no additional safety concerns, so it would not object to marketing. The product is indicated for hypovolemia and hemorrhage control in dogs, comes as a single-use kit with 20 g of freeze-dried plasma plus 250 mL sterile water for injection and an administration set, and is available by prescription through a licensed veterinarian. Before reconstitution, it can be stored in a cool, dry area at 1-25°C, with limited excursions up to 38°C for 72 hours. (fda.gov)

On use and safety, the label says the reconstituted product is equivalent to 250 mL of canine fresh frozen plasma and should be infused IV at 10-20 mL/kg, not exceeding 4-6 mL/min. FDA’s risk summary says the developer conducted three studies involving 46 dogs receiving 20 mL/kg IV, evaluating safety across blood groups, hemorrhage control in induced coagulopathy, and treatment of hypovolemia after blood loss. FDA reported adverse events including cutaneous hypersensitivity reactions and vomiting, while the product label also warns clinicians to monitor for acute or delayed hemolysis, fever, mild to severe anaphylaxis, transfusion-related acute lung injury, transfusion-associated circulatory overload, and infectious risks despite donor screening. (fda.gov)

Industry and expert commentary has focused on where cFDP could fit first. In an August 10, 2026 dvm360 interview, Kelly Mann, DVM, MS, MSS, DACVR, vice president of veterinary solutions at Mantel and affiliate faculty at Colorado State University, described the product as especially relevant for working dogs, military medicine, prehospital care, and other austere environments where access to thawed plasma is limited. She also said its potential extends beyond the battlefield into civilian emergency settings. In that same interview, Mann said the reactions seen in studies were type 1 hypersensitivity reactions such as hives, facial swelling, nausea, and occasional vomiting, and she pointed clinicians to the 2021 AVHTM transfusion reaction consensus statements for monitoring and treatment considerations. Because Mann is both a subject-matter expert and a company executive, her comments are best read as informed but not independent. (dvm360.com)

A second dvm360 interview adds a broader research lens. Mann described canine freeze-dried plasma as one piece of a larger effort to create shelf-stable whole-blood analogs, with potential spillover into synthetic cell production and molecular mimetics of blood components. He framed the work as translational, with rodent, porcine, and canine trauma research informing human care while also helping expand veterinary-specific blood products and therapeutic options. That perspective is still company-linked and forward-looking rather than independent evidence, but it helps explain why cFDP is being discussed not just as a single product launch, but as part of a wider platform for portable resuscitation tools. (dvm360.com)

Why it matters: For veterinary professionals, cFDP could be less a new indication than a new delivery model. Practices that do not keep plasma on hand because of freezer requirements, limited case volume, wastage concerns, or staffing constraints may see a shelf-stable format as a more realistic option for emergency preparedness. That could be especially relevant for general practices handling stabilization before referral, ER and critical care teams, transport programs, disaster response, and clinics serving rural areas. At the same time, this is not a low-touch product. It still requires transfusion expertise, patient selection, monitoring, and readiness to manage reactions. The current evidence base is promising but still relatively small, and some patient groups, including dogs younger than 2 years and pregnant or lactating dogs, were not specifically studied in Mantel’s program, according to Mann. (fda.gov)

The longer-term significance may be even broader. Freeze-dried plasma has been discussed as a building block for shelf-stable blood-product strategies in both human and veterinary trauma care. The 2021 Frontiers review described canine freeze-dried plasma as part of a wider pipeline that could include other resuscitation products, while Mann told dvm360 she sees freeze-dried plasma and related technologies becoming standard tools for working dog organizations over the next couple of years. In separate comments, he also linked plasma lyophilization to the broader pursuit of shelf-stable whole-blood analogs and future synthetic or mimetic blood components. That is partly an inference from the available reporting, but the trajectory suggests cFDP may be an early commercial step toward more portable transfusion support in veterinary medicine. (frontiersin.org; dvm360.com)

What to watch: The next signals to watch are peer-reviewed publication of the underlying efficacy data, real-world post-launch experience in emergency and referral settings, and whether professional guidance evolves around stocking, transfusion protocols, and reaction management for shelf-stable canine plasma. Longer term, it will be worth watching whether this line of research actually yields the broader shelf-stable whole-blood analogs, synthetic cells, or molecular mimetics that proponents see as the next frontier. (fda.gov; dvm360.com)